Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
BEFREE |
AID is mutated in hyper-IgM type 2 (HIGM2) syndrome.
|
28790320 |
2017 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
UNIPROT |
Activation induced cytidine deaminase mutant (AID-His130Pro) from Hyper IgM 2 patient retained mutagenic activity on SHM artificial substrate.
|
27716525 |
2016 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint.
|
27701145 |
2016 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
UNIPROT |
Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients.
|
26545377 |
2016 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
UNIPROT |
To our knowledge, this is a new AICDA mutation found in HIGM2 patients.
|
23803409 |
2013 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this is a new AICDA mutation found in HIGM2 patients.
|
23803409 |
2013 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
UNIPROT |
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency.
|
14962793 |
2004 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GermlineCausalMutation
|
disease |
ORPHANET |
The phenotype observed in HIGM2 patients (and in AID-/- mice) demonstrates the absolute requirement for AID in several crucial steps of B cell terminal differentiation necessary for efficient antibody responses.
|
11007475 |
2000 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
UNIPROT |
The phenotype observed in HIGM2 patients (and in AID-/- mice) demonstrates the absolute requirement for AID in several crucial steps of B cell terminal differentiation necessary for efficient antibody responses.
|
11007475 |
2000 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
Biomarker
|
disease |
BEFREE |
The phenotype observed in HIGM2 patients (and in AID-/- mice) demonstrates the absolute requirement for AID in several crucial steps of B cell terminal differentiation necessary for efficient antibody responses.
|
11007475 |
2000 |
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
Biomarker
|
disease |
CTD_human |
|
|
|
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Hyper-IgM Immunodeficiency Syndrome, Type 2
|
0.730 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Hyperimmunoglobulin M syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 42-year-old man with hyper-IgM syndrome type 2 caused by activation-induced cytidine deaminase (AID) deficiency developed a severe anaphylactic reaction to intravenous immunoglobulin.
|
29255996 |
2018 |
Hyperimmunoglobulin M syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland.
|
27142677 |
2016 |
Hyperimmunoglobulin M syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impaired immune functions leading to primary immunodeficiencies often correlate with paradoxical autoimmune complications; patients with hyper-IgM syndromes who are deficient in activation-induced cytidine deaminase (AID), which is required for class-switch recombination and somatic hypermutation, are prone to develop autoimmune diseases.
|
21700883 |
2011 |
Hyperimmunoglobulin M syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Defects in AID and UNG2 have been shown to result in the primary immunodeficiency hyper-IgM syndrome, leading us to hypothesize that additional, potentially more subtle, DNA repair gene variations may underlie the clinically related antibody deficiencies syndromes IgAD and CVID.
|
20805886 |
2010 |
Hyperimmunoglobulin M syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
S43P mutant AID has been identified in a patient with hyper-IgM immunodeficiency syndrome.
|
19022738 |
2009 |
Hyperimmunoglobulin M syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations.
|
19575287 |
2009 |
Hyperimmunoglobulin M syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A novel activation-induced cytidine deaminase gene mutation in a Tunisian family with hyper IgM syndrome.
|
15372234 |
2004 |
Hyperimmunoglobulin M syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The gene encoding activation-induced cytidine deaminase (AID) is responsible for the autosomal recessive form of hyper-IgM syndrome.
|
14564357 |
2003 |
Hyperimmunoglobulin M syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We herein report mutations in the human counterpart of AID in patients with the autosomal recessive form of hyper-IgM syndrome (HIGM2).
|
11007475 |
2000 |
Hyperimmunoglobulin M syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lymphoid hyperplasia was seen in patients with hyper IgM syndrome and normal AID as well as the patients with hyper IgM syndrome and defects in AID.
|
11112359 |
2000 |
Hyperimmunoglobulin M syndrome
|
0.400 |
Biomarker
|
disease |
CTD_human |
|
|
|